PI2 Stock Chart & Stats
€0.02
<€0.01(3.57%)
At close: 4:00 PM EST
€0.02
<€0.01(3.57%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.46M
Enterprise Value€22.37
Total Cash (Recent Filing)€781.00K
Total Debt (Recent Filing)€15.77M
Price to Earnings (P/E)―
Beta-4.84
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Proteomics ServicesThe company operates in a specialized analytical niche supporting drug discovery and biomedical research. Its fee-for-service model can generate project revenue from customers that outsource technically demanding proteomics work.
Exposure To Outsourced Research DemandOutsourcing lets pharmaceutical and biotechnology customers access complex proteomics capabilities without building equivalent internal laboratories. This creates a structurally relevant service opportunity if Proteome Sciences can win repeat projects and maintain capacity utilization.
Improving Cash Flow TrendAlthough cash generation remains negative, the much smaller 2025 cash deficit indicates improved cash discipline or working-capital performance versus the prior year. Sustaining this improvement would reduce funding pressure and support greater operating resilience.
Bears Say
Falling Revenue And Persistent LossesDeclining revenue combined with negative gross profit shows that current activity is not covering the cost base. Persistent operating and net losses weaken earnings visibility and indicate limited cost absorption, making durable profitability uncertain.
Strained Balance SheetDebt materially exceeds reported assets while equity is deeply negative, leaving limited balance-sheet flexibility. This structure increases refinancing and potential dilution risk and may constrain investment in laboratories, technology and commercial growth.
Insufficient Self-funding CapacityNegative free cash flow means operations are still not fully funding the business, despite improvement from 2024. Volatility further reduces planning certainty and could require external financing to support ongoing operations or strategic development.
Proteome Sciences News
PI2 FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is €6.46M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Apr 01, 2027 which is in 216 days.
How were Proteome Sciences PLC’s earnings last quarter?
Currently, no data Available
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in DE:PI2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.